Table of Contents

March 2, 2016

Abstract For Teens with Opioid Use Disorders, Bupe Better than Detox‐Rehab‐Relapse Providers Should Use Insurance Mandate in Pennsylvania DEA Investigates NFL Teams for Painkiller Abuse Medicaid Expansion Enabled More Recovery Services in Ohio For Suboxone, Goodbye Reckitt, Hello Spinoff Indivior Coming up (Source: Alcoholism and Drug Abuse Weekly) MedWorm Sponsor Message: Directory of the best […]

Read the full article →

UC tests whether iPads can help curb drug abuse

March 2, 2016

Researchers at the University of Cincinnati have begun studying whether iPads with facial recognition software can verify that patients are taking medications prescribed to combat drug abuse. The software from New York-based AiCure is designed to confirm that a patient ingested the right medication at the right time. The clinical study involving 140 patients focuses […]

Read the full article →

Analysis of buprenorphine/naloxone dosing impact on treatment duration, resource use and costs in the treatment of opioid-dependent adults: a retrospective study of US public and private health care claims.

March 2, 2016

CONCLUSIONS: Treatment with higher doses of buprenorphine/naloxone was associated with a longer time to treatment discontinuation, less resource use, and lower total medical costs despite higher pharmacy acquisition cost. PMID: 25295655 [PubMed – in process] (Source: Postgraduate Medicine)

Read the full article →

Primary Care–Based Buprenorphine Taper vs Maintenance Therapy for Prescription Opioid Dependence A Randomized Clinical Trial

March 2, 2016

ImportancePrescription opioid dependence is increasing and creates a significant public health burden, but primary care physicians lack evidence-based guidelines to decide between tapering doses followed by discontinuation of buprenorphine hydrochloride and naloxone hydrochloride therapy (hereinafter referred to as buprenorphine therapy) or ongoing maintenance therapy.ObjectiveTo determine the efficacy of buprenorphine taper vs ongoing maintenance therapy in […]

Read the full article →

BUPRENORPHINE AND NALOXONE Tablet [Teva Pharmaceuticals USA Inc]

March 2, 2016

Updated Date: Dec 1, 2014 EST (Source: DailyMed Drug Label Updates for the last seven days (since May 20, 2007 EST))

Read the full article →

Time to include buprenorphine-naloxone combination in the WHO Model List of Essential Medicines.

March 2, 2016

Authors: Balhara YP PMID: 24380101 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

Read the full article →

Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: development and pilot test of a clinical protocol.

March 2, 2016

CONCLUSION: Based on this experience, the protocol recommends Bup/Nx for pain only when baseline opioid doses are within bounds that reduce AEs at transition and incorporates dose flexibility to further reduce risks. This protocol warrants further testing. PMID: 23264315 [PubMed – indexed for MEDLINE] (Source: Journal of Opioid Management)

Read the full article →

Considerations on the role of buprenorphine in recovery from heroin addiction from a UK perspective

March 2, 2016

The United Kingdom Drug Strategy emphasises recovery as a key focus in the treatment of drug dependence. A framework for recovery is defined in the Recovery-Orientated Drug Treatment report, written by an expert working group, and comprises four key phases: engagement and stabilisation, including the establishment of treatment goals; preparation for change, involving engagement in […]

Read the full article →

Reversal of Opioid Overdose Syndrome in Morphine-Dependent Rats Using Buprenorphine.

March 2, 2016

Authors: Zamani N, Hassanian-Moghaddam H, Hossein Bayat A, Haghparast A, Shadnia S, Rahimi M, Demaneh BH Abstract The method of choice for reversal of opioid-toxicity is administration of naloxone. This treatment can be accompanied by complications including acute lung-injury, myocardial infarction, or withdrawal-syndrome (in dependent-patients). We aimed to evaluate the efficacy of buprenorphine in reversal […]

Read the full article →

Liver enzyme levels in adolescent patients treated with buprenorphine and additional psychotropic agents.

March 2, 2016

CONCLUSIONS: Buprenorphine/naloxone was well tolerated in most adolescent patients, besides clinically nonsignificant liver enzyme elevations. Psychotropic medications may have been associated with the liver enzyme changes early in the course of treatment. Nevertheless, given the relatively small number of adolescents studied to date with buprenorphine/naloxone, additional studies evaluating liver enzymes in young patients receiving buprenorphine/naloxone […]

Read the full article →

← Previous Entries

Next Entries →